This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EXAI Exscientia (EXAI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Exscientia Stock (NASDAQ:EXAI) Get Exscientia alerts:Sign Up Key Stats Today's Range$4.84▼$4.8450-Day Range$4.69▼$5.9652-Week Range$3.80▼$6.49VolumeN/AAverage Volume713,050 shsMarket Capitalization$632.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom. Read More Receive EXAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exscientia and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EXAI Stock News HeadlinesExscientia and Recursion Merge to Revolutionize Drug DiscoveryNovember 21, 2024 | markets.businessinsider.comRecursion, Exscientia officially combine to advance drug discoveryNovember 21, 2024 | markets.businessinsider.comStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.October 6 at 2:00 AM | Paradigm Press (Ad)Recursion: No News Isn't Good News When It Comes To Vanilla PipelineNovember 20, 2024 | seekingalpha.comBarclays Sticks to Its Hold Rating for Exscientia Plc (EXAI)November 15, 2024 | markets.businessinsider.comRecursion and Exscientia Merger Approved by ShareholdersNovember 14, 2024 | markets.businessinsider.comRecursion Pharmaceuticals: Recursion and Exscientia Shareholders Approve the Proposed CombinationNovember 13, 2024 | finanznachrichten.deRecursion, Exscientia shareholders approve proposed combinationNovember 13, 2024 | markets.businessinsider.comSee More Headlines EXAI Stock Analysis - Frequently Asked Questions How were Exscientia's earnings last quarter? Exscientia plc (NASDAQ:EXAI) released its quarterly earnings results on Thursday, August, 15th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.05. The firm had revenue of $5.60 million for the quarter. Exscientia had a negative net margin of 882.09% and a negative trailing twelve-month return on equity of 49.10%. When did Exscientia IPO? Exscientia (EXAI) raised $291 million in an initial public offering on Friday, October 1st 2021. The company issued 13,850,000 shares at a price of $20.00-$22.00 per share. What other stocks do shareholders of Exscientia own? Based on aggregate information from My MarketBeat watchlists, some other companies that Exscientia investors own include AU Optronics (AUOTY), Waste Connections (WCN), American Water Works (AWK), iShares Micro-Cap ETF (IWC), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/15/2024Today10/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EXAI CIK1865408 Webwww.exscientia.ai Phone44-0-18-6581-8941FaxN/AEmployees280Year Founded2012Profitability EPS (Trailing Twelve Months)($1.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$181.56 million Net Margins-882.09% Pretax Margin-904.93% Return on Equity-49.10% Return on Assets-33.13% Debt Debt-to-Equity Ratio0.06 Current Ratio4.54 Quick Ratio4.54 Sales & Book Value Annual Sales$25.60 million Price / Sales24.72 Cash FlowN/A Price / Cash FlowN/A Book Value$2.54 per share Price / Book1.91Miscellaneous Outstanding Shares130,770,000Free Float109,324,000Market Cap$632.93 million OptionableOptionable Beta0.83 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:EXAI) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIs This Warren’s Buffett’s #1 AI Investment?Did you know that Warren Buffett is investing in what Jeff Brown believes will be the next generation of artif...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredWarren Buffett’s #1 AI Stock is Not Even on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A Millionaire With SEVEN Clicks? $1,000 in just seven stocks in 2004 could have turned into a million-dolla...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exscientia plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Exscientia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.